ASH 2021 | Tandem transplantation for patients with myeloma with high-risk cytogenetics
Hermann Einsele
• 7 Dec 2021
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, discusses the role of tandem autologous stem cell transplantation (ASCT) in multiple myeloma. Recently reported results from the Phase III EMN02/HO95 trial (NCT01208766) showed that tandem transplantation provided higher response rates and longer progression-free survival, compared to single transplantation, in patients with newly diagnosed myeloma. This improvement was most notable in patients with a high-risk cytogenetic profile. Prof. Einsele comments that most centers across Europe are now offering tandem transplantation to high-risk patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
